Acute rheumatic fever and rheumatic heart disease, Jones criteria, secondary prophylaxis, NT/Qld high-prevalence

Definition / Overview

• Acute rheumatic fever (ARF) is a delayed autoimmune sequela of group A streptococcal (GAS) pharyngitis, occurring 2 to 4 weeks after untreated or inadequately treated infection.
• Rheumatic heart disease (RHD) develops from recurrent or severe episodes of ARF, resulting in permanent valvular damage, predominantly affecting the mitral and aortic valves.
• In Australia, ARF and RHD represent one of the starkest health inequities, with incidence rates in Aboriginal and Torres Strait Islander communities in northern Australia ranking among the highest globally.
• While rare in non-Indigenous populations, rates in some remote Top End communities exceed 380 cases per 100,000 population annually, a rate 100 times higher than non-Indigenous Australians.
• The disease disproportionately affects children aged 5 to 14 years, though initial presentations can occur into the mid-twenties.
• RHD develops in approximately 60% of individuals after a single ARF episode without secondary prophylaxis, and approaches 100% after recurrent episodes.
• The burden falls predominantly on communities in the Northern Territory, Far North Queensland, northern Western Australia, and northern South Australia, correlating with poverty, household crowding, and limited access to primary healthcare.
• Clinical Pearl: Every ARF case represents a failure of primary prevention.
• Every RHD death represents a failure of secondary prevention.
• This is an entirely preventable condition.

Pathophysiology

• ARF results from molecular mimicry between GAS M-protein antigens and human cardiac tissue, synovium, basal ganglia, and dermal collagen.
• Following GAS pharyngitis (not skin infections), susceptible individuals mount cross-reactive antibodies and T-cell responses targeting cardiac myosin, valvular endothelium, and other tissues.
• Genetic susceptibility plays a role, with certain HLA types and familial clustering observed in high-prevalence populations.
• The latent period between pharyngitis and ARF onset is typically 2 to 4 weeks.
• During this window, anti-streptococcal antibody titres rise.
• The acute inflammatory cascade damages cardiac valves (carditis), joints (arthritis), subcutaneous tissue (nodules), skin (erythema marginatum), and basal ganglia (Sydenham chorea).
• Pancarditis affects endocardium, myocardium, and pericardium during acute episodes.
• Recurrent ARF episodes cause cumulative valve damage.
• Initial episodes typically produce valvular regurgitation (mitral more than aortic).
• Repeated inflammation leads to progressive fibrosis, calcification, commissural fusion, and eventually stenosis.
• The mitral valve is affected in 75% to 80% of RHD cases, often with mixed stenosis and regurgitation.
• Aortic involvement occurs in 30%, usually with coexistent mitral disease.
• Isolated aortic or tricuspid disease is rare.
• Right-sided failure develops in advanced cases.

Environmental factors driving high ARF rates in northern Australian Indigenous communities include:

• Household overcrowding (often 10+ persons per dwelling)
• Poor housing quality and inadequate hygiene facilities
• High background rates of GAS pharyngitis (endemic transmission)
• Barriers to healthcare access in remote settings
• Co-morbid conditions (scabies, skin sores, otitis media)

The NT Department of Health estimates that without intervention, ARF incidence would continue rising given ongoing social determinants.

Clinical Features

Acute Rheumatic Fever Presentation

• ARF diagnosis requires application of the Australian guideline-modified Jones criteria, endorsed by RHDAustralia and used nationally since 2012.
• These criteria differ from the 2015 American Heart Association revision and are specifically designed for moderate-to-high-risk populations.

Australian Modified Jones Criteria (for high-risk populations):

Evidence of recent GAS infection (elevated or rising anti-streptolysin O titre, positive throat swab, or scarlet fever) PLUS either:

• 2 major criteria, OR
• 1 major + 2 minor criteria

Major manifestations detail:

1. Carditis (50 to 70% of cases): Presents with new murmur (mitral or aortic regurgitation), tachycardia disproportionate to fever, cardiac enlargement, or pericardial rub. Subclinical carditis detected by echocardiography (valvular regurgitation with morphological changes) is sufficient as a major criterion under Australian guidelines. This inclusion increases diagnostic sensitivity in high-risk populations.

2. Arthritis (70 to 75%): Classically a migratory polyarthritis affecting large joints (knees, ankles, elbows, wrists) with rapid response to NSAIDs. In high-risk populations, monoarthritis or even polyarthralgia qualifies as a major criterion. Joint involvement typically resolves within days to weeks without permanent damage.

3. Chorea (10 to 30%): Sydenham chorea manifests as involuntary, purposeless movements, emotional lability, and motor impersistence (inability to maintain sustained muscle contraction, e.g. "milkmaid's grip"). Often has a longer latency (2 to 6 months post-infection) and may occur in isolation without other criteria. More common in females.

4. Erythema marginatum (<5%): Pink, non-pruritic, serpiginous rash with central clearing, typically on trunk and proximal limbs. Evanescent and difficult to capture.

5. Subcutaneous nodules (<5%): Painless, firm nodules over bony prominences or extensor surfaces. Rare in isolation.

• Red Flag: Carditis determines prognosis.
• Always perform careful cardiovascular examination and arrange echocardiography in all suspected ARF cases.
• Even mild regurgitation requires long-term follow-up.

Evidence of GAS Infection

Anti-streptolococcal antibodies peak 3 to 6 weeks post-infection:

• Anti-streptolysin O (ASO) titre >200 IU in adults, >320 IU in children (laboratory-specific)
• Anti-DNase B titre particularly useful as remains elevated longer
• Rising titres (two samples 2 weeks apart) more specific than single elevated value
• Throat swab culture is positive in only 25 to 40% at presentation due to the latent period.
• Rapid antigen detection tests have low sensitivity (60%).

Rheumatic Heart Disease Presentation

• RHD develops silently over years following recurrent ARF.
• Many patients in remote Australia present late with established disease, having never received a documented ARF diagnosis.

Clinical features depend on valve lesions:

• Mitral stenosis: Mid-diastolic murmur, opening snap, malar flush, atrial fibrillation (AFib), pulmonary hypertension, right heart failure
• Mitral regurgitation: Pansystolic murmur radiating to axilla, displaced apex, pulmonary oedema
• Aortic regurgitation: Early diastolic murmur, wide pulse pressure, collapsing pulse
• Mixed lesions: Overlapping features

Complications include AFib with thromboembolism (25% of RHD patients), infective endocarditis (10% lifetime risk), heart failure, pulmonary hypertension, and pregnancy-related decompensation.

• Clinical Pearl: Many RHD patients in the Top End present in their 30s with advanced disease requiring valve surgery, having missed childhood ARF diagnosis and secondary prophylaxis opportunities.
• This represents a critical prevention failure point.

Investigations

ARF Diagnosis

1. Throat swab: For GAS culture and rapid antigen testing
2. Anti-streptococcal serology: ASO titre, anti-DNase B
3. Inflammatory markers: ESR, CRP (both often markedly elevated)
4. ECG: PR prolongation (first-degree AV block), conduction abnormalities
5. Echocardiography: MANDATORY in all cases. Assess for valvular regurgitation, chamber dimensions, ventricular function. Doppler assessment of regurgitant jets. Subclinical carditis detection. Baseline for follow-up.
6. Blood cultures: If febrile, to exclude infective endocarditis
7. Full blood count: Anaemia, leucocytosis

RHD Screening and Surveillance

Echocardiographic screening programs operate in high-prevalence regions (NT, Far North Queensland, Kimberley WA). The RHDAustralia guidelines recommend:

• All ARF patients: Echo at diagnosis, 6 weeks, 1 year post-episode, then annually
• Known RHD: Echo annually or 6-monthly if moderate-to-severe disease
• School-based screening: Ages 5 to 19 years in high-prevalence areas
• Echo findings in RHD include valvular thickening, restricted leaflet motion, subvalvular thickening, commissural fusion, and regurgitant or stenotic jets.
• Severity grading guides management and surgical referral.

Investigations for RHD complications:

• Holter monitor/ECG: AFib detection
• Transthoracic/transoesophageal echo: Pre-operative assessment, endocarditis diagnosis
• Cardiac MRI: Selected cases for myocardial assessment
• BNP/NT-proBNP: Heart failure monitoring
• CXR: Cardiac size, pulmonary oedema, valve calcification

Management

Acute Rheumatic Fever

Immediate management:

1. Treat GAS infection: Benzathine benzylpenicillin G (BPG) 900mg (1.2 million units) IM for ≥20kg, 450mg (<20kg) single dose. This eradicates pharyngeal carriage and initiates secondary prophylaxis. Alternatives: phenoxymethylpenicillin 500mg PO BD for 10 days (if IM refused), or erythromycin 500mg PO BD for penicillin allergy.

2. Anti-inflammatory therapy: Aspirin 50 to 100mg/kg/day (maximum 4g/day) divided QID for arthritis. Continue until inflammatory markers normalise (typically 4 to 6 weeks), then taper over 2 weeks. If severe carditis with heart failure, consider prednisolone 1 to 2mg/kg/day for 2 to 3 weeks, then taper.

3. Heart failure management: Restrict salt/fluid, frusemide, ACE inhibitor if significant regurgitation or LV dysfunction. Bed rest during acute carditis phase.

4. Chorea: Usually self-limiting over 3 to 6 months. Severe cases may require sodium valproate or carbamazepine. Avoid neuroleptics (risk of extrapyramidal effects).

• Notification and registration: ARF is notifiable in all Australian jurisdictions.
• Every case must be registered on the RHDAustralia national register (coordinated through jurisdiction-based RHD control programs).

Secondary Prophylaxis

• Secondary prophylaxis with long-acting benzathine benzylpenicillin G is the cornerstone of RHD prevention.
• It prevents recurrent GAS pharyngitis and thus recurrent ARF.
• Regimen: BPG 900mg (≥20kg) or 450mg (<20kg) IM every 28 days.
• In very high-risk settings (Top End NT, Far North Queensland remote communities), 21-day dosing intervals are used due to demonstrated higher rates of breakthrough ARF on 28-day regimens.

Duration of prophylaxis:

• Adherence challenges: Achieving adequate adherence in remote settings requires intensive outreach.
• RHD control programs employ dedicated nurses, recall systems, and community health worker models.
• Even with optimal programs, adherence to ≥80% of scheduled doses proves difficult.
• Innovations include nurse-led outreach clinics, reminder SMS systems, and incentive programs.

For genuine penicillin allergy, erythromycin 250mg PO BD is an alternative, though oral adherence is substantially poorer.

• High-Yield: Secondary prophylaxis adherence directly correlates with RHD progression rates.
• Missing >20% of doses doubles the risk of recurrent ARF.

RHD-Specific Management

Medical therapy:

• AFib: Rate/rhythm control, anticoagulation (warfarin, target INR 2.5 to 3.5 if mechanical valve)
• Heart failure: ACE inhibitor, beta-blocker, diuretics
• Endocarditis prophylaxis: Amoxicillin 2g PO 1 hour before high-risk dental procedures (eTG complete guidelines)
• Surgical intervention: Indications include severe symptomatic stenosis, severe regurgitation with LV dilatation/dysfunction, or heart failure refractory to medical therapy.
• Options include mitral valve repair, replacement (mechanical or bioprosthetic), balloon valvuloplasty for pure mitral stenosis.
• Mechanical valves require lifelong warfarin; bioprosthetic valves degenerate faster in young patients.
• Surgical services for remote patients typically occur in tertiary centres (Royal Darwin Hospital, Townsville Hospital, Perth metropolitan).
• Pregnancy in RHD: High-risk scenario.
• Increased cardiac output exacerbates valve lesions.
• Management requires specialist obstetric cardiology input.
• Delivery planning at tertiary centre.
• Anticoagulation management complex (warfarin teratogenic first trimester; heparin bridging regimens).

Red Flags

• Red Flag: Diagnostic pitfalls include failing to consider ARF in an Aboriginal child with fever and joint pain.
• The differential includes septic arthritis, reactive arthritis, and juvenile idiopathic arthritis, but in a Top End or Far North Queensland setting, ARF must be top of the list.
• Red Flag: New or worsening murmur in a known RHD patient, especially with fever, raises concern for infective endocarditis.
• Blood cultures and urgent echo mandatory.
• Red Flag: Pregnancy in a woman with moderate-to-severe RHD requires immediate specialist referral.
• Maternal and foetal mortality risks are substantial without expert care.
• Red Flag: Stroke in a young Aboriginal adult should prompt investigation for RHD with AFib and cardiac thrombus.
• Many undiagnosed cases present this way.
• Red Flag: Missed BPG doses in the first 2 years post-ARF diagnosis carry the highest risk for recurrent ARF.
• Intensive recall efforts are essential in this window.

Australian Context

Epidemiology and Burden

• Australia's ARF/RHD incidence is bimodal.
• Non-Indigenous Australians have rates similar to other high-income countries (<1 per 100,000).
• In contrast, Aboriginal and Torres Strait Islander populations in northern Australia experience rates comparable to the poorest global regions.
• The Northern Territory Top End reports ARF incidence exceeding 380 per 100,000 in some remote communities, with RHD prevalence around 2% in adults.
• Queensland's Cape York and Torres Strait regions, the Kimberley in Western Australia, and APY Lands in South Australia also report high rates.
• Approximately 500 ARF cases are diagnosed annually in Australia, 95% in Aboriginal and Torres Strait Islander people.
• RHD affects at least 5,300 Australians, with >80% Aboriginal and Torres Strait Islander.
• Premature mortality is substantial: median age of RHD death is 44 years for Aboriginal people versus 72 years for non-Indigenous Australians.
• RHD is the leading cause of cardiovascular death in Aboriginal and Torres Strait Islander people aged 5 to 44 years.

RHDAustralia and Control Programs

• RHDAustralia is the national coordinating body, providing evidence-based guidelines, clinical resources, and the national RHD register.
• The register enables tracking, recall, and audit.

Jurisdiction-based control programs operate in:

• Northern Territory: NT RHD program (most established, outreach model with dedicated nurses)
• Queensland: Queensland RHD program covering Far North Queensland
• Western Australia: Kimberley RHD program
• South Australia: APY Lands services
• These programs employ a public health approach: primary prevention (treat GAS pharyngitis), secondary prevention (BPG delivery and adherence support), and tertiary prevention (specialist cardiology, surgical referrals, echo surveillance).
• The NT program pioneered nurse-led community outreach models, now replicated elsewhere.
• Clinical Pearl: The RHDAustralia guidelines differ from international guidelines (2015 AHA Jones criteria) by including monoarthritis and polyarthralgia as major criteria and allowing subclinical echo-detected carditis.
• These modifications increase diagnostic sensitivity in high-prevalence populations.

MBS and Service Delivery

• Indigenous-specific MBS items support chronic disease care, though ARF/RHD-specific items are limited.
• Item 715 (Aboriginal health check) facilitates opportunistic RHD screening.
• Remote area Aboriginal health services (funded federally) are key delivery points for BPG.
• State-funded retrieval services (CareFlight Queensland, MedSTAR Darwin, RFDS) transfer ARF and decompensated RHD patients to tertiary centres.
• Barriers to care include geographic remoteness (some communities 500+ km from hospital), staff turnover in remote clinics, cultural factors affecting healthcare engagement, and competing health priorities (diabetes, renal disease, trauma).
• Innovative solutions include telehealth cardiology consultations, annual specialist outreach clinics, and training Aboriginal health practitioners to administer BPG.

Policy and Targets

• The Australian Government's Closing the Gap targets include reducing the RHD burden, though specific numerical targets remain contentious.
• The National Aboriginal and Torres Strait Islander Health Plan identifies RHD as a priority.
• State-based strategic plans in the NT, Queensland, and WA outline RHD elimination goals by 2031.
• Progress is slow: ARF incidence has plateaued rather than declined over the past decade, attributed to persistent social determinants.
• The END RHD Centre of Research Excellence (based at the Menzies School of Health Research, Darwin) coordinates national research efforts.
• Key research areas include primary prevention strategies (primordial prevention), vaccine development (GAS vaccine in phase 2 trials), optimal BPG dosing intervals, and health systems strengthening.

Key Points

1. High-Yield: ARF and RHD are rare in non-Indigenous Australians but endemic in northern Aboriginal communities, with Top End NT incidence rates among the world's highest. This represents Australia's starkest health inequality.

2. Diagnosis requires modified Jones criteria: In high-risk populations, monoarthritis or polyarthralgia count as major criteria, and subclinical echo-detected carditis is sufficient for diagnosis. Always obtain echocardiography in suspected cases.

3. Secondary prophylaxis with BPG is critical: Benzathine benzylpenicillin G 900mg IM every 28 days (or 21 days in very high-risk settings) prevents recurrent ARF and RHD progression. Duration depends on carditis severity, ranging from 5 years to lifelong. Adherence determines outcomes.

4. RHDAustralia coordinates national efforts: The national register, evidence-based guidelines, and jurisdiction-based control programs (NT, Queensland, WA) provide the infrastructure for case detection, prophylaxis delivery, and echo surveillance.

5. Carditis determines prognosis: Approximately 60% develop RHD after untreated ARF. Recurrent episodes accelerate valve damage. Mitral valve involvement dominates, often progressing to stenosis requiring surgical intervention in the third or fourth decade.

6. Social determinants drive disease: Household overcrowding, poor housing quality, and limited healthcare access in remote communities sustain high GAS transmission rates. Addressing RHD requires addressing poverty and housing.

7. Every case is preventable: ARF follows inadequately treated GAS pharyngitis. RHD follows inadequate secondary prophylaxis. Failures in primary and secondary prevention, not individual pathology, explain the ongoing epidemic.

8. Red flags for finals: New murmur in a febrile Aboriginal child from northern Australia is ARF until proven otherwise. Stroke in a young Aboriginal adult requires RHD with AFib exclusion. Pregnancy in known RHD mandates specialist input due to high maternal-foetal risk.